Why Every GLP-1 User Needs a Medication Level Chart
Understanding your semaglutide or tirzepatide levels helps you time side effects, understand dose changes, and know when your medication is actually working.
You inject once a week. You might feel nauseous on day two, fine by day five, and wonder on day six whether the medication is still doing anything at all. That rollercoaster of effects and uncertainty is completely normal, and there is a straightforward way to make sense of it: a medication level chart.
This is not a vague “trust the process” article. We are going to look at the actual pharmacokinetics of semaglutide and tirzepatide, what happens in your body between injections, and why understanding your estimated drug levels changes everything about how you experience GLP-1 therapy.
What is a pharmacokinetic curve?
Pharmacokinetics (PK) is the study of how a drug moves through your body over time: absorption, distribution, metabolism, and elimination. A PK curve plots your estimated blood concentration of a medication on a graph, with time on the horizontal axis and drug level on the vertical axis.
Think of it like a bathtub. When you inject, you turn on the tap. The water level (drug concentration) rises over the first day or two until it hits a peak. Then the tap slows to a trickle while the drain stays open. The water level gradually drops until your next injection, when the tap opens again.
That peak is called Cmax — the maximum concentration. The lowest point, right before your next dose, is your trough. The time it takes to reach the peak is Tmax. And the total exposure over one dosing interval is the AUC (area under the curve).
These are not abstract lab concepts. They directly map to your lived experience on a GLP-1 medication:
- Cmax is often when side effects are strongest
- Trough is when appetite suppression may feel weakest
- AUC reflects your total drug exposure, which drives efficacy over time
A PK chart turns these invisible processes into something you can actually see.
Why knowing your medication level matters
Timing side effects
Nausea, GI discomfort, and reduced appetite are the most commonly reported side effects of GLP-1 medications. They are also concentration-dependent, meaning they tend to be worse when your drug level is highest.
For injectable semaglutide (Ozempic, Wegovy), Tmax is 1-3 days post-injection, with a median around 36 hours. That lines up precisely with when most people report their worst nausea: day one through day three after injecting.
For tirzepatide (Mounjaro, Zepbound), Tmax is 8-72 hours post-injection, with a median around 24 hours. Many tirzepatide users notice a faster onset of side effects and a slightly earlier window of peak nausea compared to semaglutide.
Knowing this changes your relationship with side effects. Instead of “why do I feel terrible today?” it becomes “I’m at peak concentration right now — this is expected, and it will ease over the next few days.” That reframe is genuinely empowering. You can plan around it: schedule lighter meals on peak days, avoid rich foods during days 1-3, and know that by day 5 or 6, your levels have dropped significantly from their peak.
This is not about making side effects disappear. It is about understanding them well enough to stop being afraid of them.
Understanding dose escalation
One of the most confusing moments in GLP-1 therapy is titrating up. You have been on 0.25 mg semaglutide for four weeks, you felt fine by week three, and now you move to 0.5 mg and the nausea comes roaring back. What happened?
The PK curve explains it clearly. When you dose weekly, each injection stacks on top of the residual drug still in your system from the previous dose. Over 4-5 weeks, your levels accumulate until they stabilize at what is called steady state. At steady state on 0.25 mg, your trough level sits at a certain concentration.
When you jump to 0.5 mg, your new trough will eventually settle higher than your old peak at 0.25 mg. Read that again: your lowest point on the new dose is higher than your highest point on the old dose. Of course side effects return. Your body is adjusting to an entirely new concentration range.
This is why titration schedules exist. The standard Wegovy titration (0.25 mg for 4 weeks, then 0.5 mg for 4 weeks, then 1 mg, then 1.7 mg, then 2.4 mg) is designed to let your body reach steady state at each level before pushing higher. Skipping steps or shortening the interval is not “getting to the effective dose faster.” It is slamming your body with a concentration jump it has not adapted to.
A medication level chart makes this accumulation visible. You can see the stacking effect, watch the trough rise with each new dose tier, and understand exactly why your body is responding the way it is.
Knowing when it is actually working
This might be the most important one. GLP-1 medications take time to reach full effectiveness, and most people start judging results far too early.
Semaglutide has a half-life of approximately 7 days (168 hours). Steady state takes 4-5 half-lives to achieve. That means it takes roughly 5 weeks of consistent weekly dosing before your levels stabilize at any given dose.
For tirzepatide, with a half-life of approximately 5 days (120 hours), steady state arrives a bit sooner — around 3.5 to 4 weeks.
What does this mean in practice? If you started Ozempic at 0.25 mg two weeks ago and you are not seeing weight loss, that is not a sign the medication is failing. You are still accumulating. Your drug level at week two is meaningfully lower than it will be at week five. Judging efficacy before steady state is like judging a marathon runner’s pace from the first 200 meters.
A PK chart shows you exactly where you are on that accumulation curve. It answers the question “is this working yet?” with data instead of anxiety.
How half-life works for GLP-1 medications
Half-life is the time it takes for half the drug to be eliminated from your body. It is the single most important number for understanding your medication’s behavior between doses.
Semaglutide: ~7 day half-life
Semaglutide (Ozempic, Wegovy, Rybelsus) has a half-life of approximately 168 hours — almost exactly 7 days. This is not a coincidence; it is why semaglutide is dosed once weekly. After one week, roughly half the drug from your last injection is still circulating. After two weeks without dosing, about 25% remains. After three weeks, about 12.5%.
That long half-life is actually a feature. It means your drug levels do not swing wildly between doses. The peak-to-trough ratio is relatively gentle, which translates to more consistent appetite suppression and fewer dramatic side effect windows.
The accumulation ratio for semaglutide is approximately 3-fold. In plain terms: once you reach steady state, your trough level is about 3 times higher than it would be after a single dose. This is normal and expected. Your body is not “building up too much drug.” It is reaching its designed operating level.
Tirzepatide: ~5 day half-life
Tirzepatide (Mounjaro, Zepbound) has a shorter half-life of approximately 120 hours — about 5 days. It is still dosed weekly, but because it clears faster, the peak-to-trough swing is wider than semaglutide.
What does this mean for you? Potentially more noticeable fluctuations in appetite suppression and side effects across the week. Some tirzepatide users report feeling the medication “wear off” by day 6 or 7 more than semaglutide users do. The PK curve confirms this: tirzepatide drops further between doses.
Why half-life matters for side effects
Longer half-life = smoother levels = smaller swings between peak and trough = potentially fewer side-effect spikes.
This is also why some people who split their semaglutide dose (injecting half the dose twice per week instead of the full dose once weekly) report fewer side effects. Splitting the dose reduces the Cmax while maintaining a similar AUC — you get a flatter, smoother curve. The peaks are lower, so the concentration-dependent side effects (especially nausea) are less intense.
Note: dose splitting is not recommended by Novo Nordisk or in the prescribing information. But the pharmacokinetics explain why some people and some clinicians explore it. Understanding the math does not mean you should change your protocol on your own — it means you can have an informed conversation with your prescriber if your side effects are difficult to manage.
What a PK chart shows you that a simple dose log does not
A dose log tells you what you took and when. That is useful, but it is a flat record. A PK chart transforms that same data into a continuous picture of what is happening in your body between doses. Here is what it reveals:
Accumulation over time
Your first injection of semaglutide 0.25 mg produces a relatively small peak. Your second injection one week later stacks on top of the residual drug from dose one — the peak is higher, and the trough is higher. By week four or five, each dose adds roughly the same amount that is being eliminated, and your levels stabilize.
On a dose log, weeks one through five look identical: “0.25 mg, injected.” On a PK chart, you see a staircase pattern rising to a plateau. That visual makes the concept of accumulation intuitive.
Peak-to-trough ratio
How much do your levels swing during a single dosing interval? For semaglutide, the ratio is relatively modest because of the long half-life. For tirzepatide, it is wider. For someone who switched from one to the other, overlaying both curves shows exactly why the experience feels different.
This ratio also matters for side effects. A medication with a high peak-to-trough ratio produces sharper spikes in concentration, which can mean more intense but shorter-lasting side effects. A flatter curve means milder but more sustained effects.
Steady state visualization
Without a PK chart, “steady state takes 5 weeks” is an abstract statement. With a chart, you can literally see the curve flattening out — the peaks and troughs stop climbing and begin oscillating within a stable band. You can point to the moment on the graph where your levels stopped changing meaningfully, and that is when you can fairly evaluate whether a dose is working for you.
Dose change comparisons
If you titrate from 0.5 mg to 1 mg semaglutide, a PK chart shows you the transition: the old steady state declining, the new accumulation building, and the point where you reach the new steady state. It can also show you why going back down a dose does not immediately feel like it used to — your levels take several weeks to fall back to the lower steady state.
Multi-medication context
Many GLP-1 users are also taking metformin, a statin, a thyroid medication, or other drugs. While PK modeling for drug interactions is complex and beyond what an estimation tool should claim, simply seeing multiple medications on the same timeline helps you correlate patterns. Started metformin the same week you titrated up on semaglutide? The chart helps you see that two things changed at once, which matters when you are trying to figure out what caused a new side effect.
Try it yourself
All of this is easier to understand when you can see your own protocol on a chart instead of reading about hypothetical curves.
Doseline’s free Medication Level Plotter lets you visualize your exact protocol — select your medication, enter your dose and frequency, and see the curve. Add a dose change and watch the transition play out. Compare semaglutide and tirzepatide side by side. See when you will reach steady state.
No account required. No data stored. Just the math, applied to your protocol.
Stop guessing, start seeing
GLP-1 medications are powerful tools, but they are also slow-acting, accumulation-dependent drugs that behave in ways your intuition might not predict. A medication level chart bridges the gap between “I injected on Tuesday” and “here is what my estimated drug concentration looks like right now, and here is why I feel the way I do.”
Understanding your PK curve will not eliminate side effects or make the weight come off faster. But it replaces confusion with clarity, anxiety with expectation, and guesswork with data. And for most people, that changes the entire experience.
Track your actual doses, weight, and side effects alongside your estimated medication levels in the Doseline app — coming soon.
Doseline provides informational tools, not medical advice. Pharmacokinetic estimates are based on published population averages and may not reflect your individual response. Always work with your healthcare provider on dosing decisions.